Pinealon is a synthetic tripeptide with the sequence Glu-Asp-Arg (EDR), studied in laboratory research as a short "peptide bioregulator" — a class of ultrashort peptides investigated for direct interaction with DNA and for effects on neuronal gene expression under oxidative and hypoxic stress. Published work is confined to cell-culture systems, rodent models, and a small number of observational human reports from a single research lineage; there are no completed randomized controlled trials. This overview covers its chemistry, the proposed mechanisms, what the peer-reviewed record actually shows, its limitations, and how the material is handled in the lab.
Research Background
Pinealon belongs to the family of short peptide bioregulators characterized from the 1970s onward at the St. Petersburg Institute of Bioregulation and Gerontology and the Pavlov Institute of Physiology, largely under Vladimir Khavinson and colleagues. The same research program produced Epitalon (Ala-Glu-Asp-Gly, AEDG), Vilon (Lys-Glu, KE), Thymogen (Glu-Trp, EW), and Vesugen (Lys-Glu-Asp, KED). Pinealon is the tripeptide member most consistently associated with neuronal and central-nervous-system research models.
The organizing hypothesis behind the whole family is that peptides of two to seven residues are small enough to cross cell and nuclear membranes intact and to interact directly with nucleic acids and chromatin proteins, rather than acting only through cell-surface receptors. Pinealon has been used repeatedly as a test case for that hypothesis, because its charged Glu-Asp-Arg sequence is a plausible candidate for sequence-selective DNA contact.
Two caveats belong up front. First, the great majority of the Pinealon literature originates from a small number of affiliated Russian groups, and independent replication by unaffiliated laboratories is sparse. Second, "Pinealon" is a trade-style name attached to the EDR sequence; the peptide is chemically synthesized, not extracted from pineal tissue, despite the name's implication.
Chemistry and Physical Properties
| Property | Value |
|---|---|
| Sequence | Glu-Asp-Arg (EDR) |
| Length | 3 residues |
| Molecular weight | ~418.41 g/mol |
| CAS number | 175175-23-2 |
| Form supplied | Lyophilized powder |
| Net charge at physiological pH | Net negative (two acidic residues, one basic) |
The two acidic side chains (Glu, Asp) paired with a single guanidinium group (Arg) give the molecule a mixed charge distribution, which is the structural feature most often invoked in the DNA-interaction literature. At roughly 418 daltons, EDR is far below the size at which passive membrane permeability becomes prohibitive, which is consistent with the reported intracellular and intranuclear localization discussed below.
Proposed Mechanisms in Research Models
Direct nuclear entry and DNA interaction
The most distinctive claim in the Pinealon literature is that the intact tripeptide reaches the nucleus. A 2011 study in Biochemistry (Moscow) incubated HeLa cells with fluorescein isothiocyanate-labeled short peptides — including pinealon (EDR), epithalon (AEDG), and testagen (KEDG) — and reported marked fluorescence in cytoplasm, nucleus, and nucleolus. The same paper used fluorescence-quenching measurements against labeled deoxyribooligonucleotides and reported that binding differed by peptide primary structure, that the peptides discriminated between nucleotide sequences, and that epithalon, pinealon, and bronchogen bound preferentially to oligonucleotides containing CNG sequences — the sites targeted by cytosine methylation in eukaryotes. The authors also reported that binding was sensitive to the methylation status of the cytosines.
A 2019 biophysical study in the Journal of Physical Chemistry B examined the EDR–DNA interaction directly using spectral methods, NMR, viscosimetry, and molecular dynamics. It reported that EDR can partially penetrate the major groove of DNA and contact base atoms — principally the N7 and O6 positions of guanine — and that Mg²⁺ ions promoted the interaction by screening the negatively charged phosphate backbone. This is one of the few Pinealon-adjacent datasets generated by a physics group rather than the originating peptide laboratory, and it is useful precisely because it measures a physical interaction rather than a downstream biological outcome.
Oxidative-stress and cell-viability pathways
A 2011 paper in Rejuvenation Research reported that pinealon produced dose-dependent restriction of reactive oxygen species accumulation in rat cerebellar granule cells, neutrophils, and PC12 pheochromocytoma cells under receptor-dependent and receptor-independent oxidative stress. The same study reported decreased necrotic cell death by propidium iodide staining, a delayed time course of ERK 1/2 activation, and modification of the cell cycle. The authors noted that ROS restriction saturated at lower concentrations while cell-cycle modulation continued at higher concentrations, and interpreted this dissociation as evidence for a genomic action distinct from simple antioxidant chemistry.
Gene-expression effects
A 2014 report in Bulletin of Experimental Biology and Medicine found that EDR and KED increased serotonin expression in aging rat brain cortex cell cultures, and used molecular docking to propose interaction with the tryptophan hydroxylase gene encoding the rate-limiting enzyme of serotonin synthesis. The authors identified a CCTGCC nucleotide stretch in that gene as complementary to the peptides.
A 2020 review in Molecules consolidated the mechanistic picture for EDR specifically, proposing that the peptide enters cells and binds histone proteins and/or nucleic acids, and describing reported downstream changes in MAPK/ERK signaling, proapoptotic proteins (caspase-3, p53), antioxidant enzymes (SOD2, GPX1), the transcription factors PPARA and PPARG, serotonin, and calmodulin. That review also summarized reports that EDR interferes with dendritic-spine elimination in neuronal cultures derived from mouse models of Alzheimer's and Huntington's disease, and that it activates antioxidant enzyme synthesis in rat cerebellar neuron culture.
Published Research Overview
In vitro
The most methodologically current in-vitro dataset is a 2024 study in the International Journal of Molecular Sciences. The authors built a human neuronal aging model by transdifferentiating dermal fibroblasts from elderly donors into induced cortical neurons, then treated them with EDR, KED, and AEDG. Reported results: all three peptides promoted dendritic arborization, increasing both the number of primary processes and total dendrite length; EDR specifically reduced oxidative DNA damage in induced neurons from elderly donors; and none of the tripeptides changed mitochondrial or lysosomal activity or p16 protein levels.
That last point is worth emphasizing for study design. The reported effect was selective — morphological and DNA-damage endpoints moved while canonical senescence and organelle-activity endpoints did not. A researcher planning an experiment around this compound should choose endpoints accordingly rather than assuming a broad anti-senescence effect.
Animal models
A 2008 paper in Advances in Gerontology (Uspekhi Gerontologii) evaluated several short peptides — vilon, epitalon, vesugen, and pinealon — in a hypobaric hypoxia model, reporting antihypoxic properties with pinealon showing the most pronounced effect among them. In prenatal hypoxia experiments, the author attributed increased neuronal resistance less to direct suppression of ROS accumulation than to stimulation of endogenous antioxidant enzyme systems (superoxide dismutase, glutathione peroxidase), with a possible contribution from limiting NMDA-mediated excitotoxicity. This paper is in Russian with an English abstract, which limits how far its methods can be independently assessed.
Human literature
A small number of observational human reports exist, mainly in Russian gerontology journals, and are noted here only as scientific context. They are not controlled trials, are not independently replicated, and do not establish any effect of any product. The 2020 Molecules review characterizes the EDR human record as reports of normalized behavioral responses in animal studies and improved memory measures in elderly patients — a description of published claims, not a demonstrated outcome.
Limitations of the evidence base
- Concentration in one research lineage. Most Pinealon papers trace to the Khavinson group and affiliated St. Petersburg institutes. The 2019 J. Phys. Chem. B DNA-binding study and, partially, the 2024 induced-neuron study are the useful exceptions.
- No randomized controlled trials. As of 2026, no completed RCT of EDR appears in the indexed literature.
- Publication-language and access barriers. Several key animal papers are Russian-language with English abstracts only.
- Mechanism remains a hypothesis. Direct nuclear DNA interaction is supported by biophysical and imaging data, but the causal chain from DNA binding to the reported cellular endpoints has not been demonstrated end to end.
2026 status
The field remains active but has not advanced past preclinical work. A January 2026 review in the Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews surveyed peptides in musculoskeletal and recovery contexts and grouped pinealon with epithalon and DSIP as agents reported to target circadian and mitochondrial regulators — while stating explicitly that, despite promising preclinical studies, clinical trials are currently lacking. That characterization is an accurate summary of where EDR stands: a mechanistically interesting research tool with a preclinical-only evidence base.
Pinealon Compared With Related Short Peptide Bioregulators
| Compound | Sequence | Primary research context |
|---|---|---|
| Pinealon | Glu-Asp-Arg (EDR) | Neuronal oxidative stress, hypoxia models, DNA interaction |
| Epitalon | Ala-Glu-Asp-Gly (AEDG) | Telomerase and pineal/circadian research |
| Vesugen | Lys-Glu-Asp (KED) | Vascular and neuronal gene-expression models |
| Vilon | Lys-Glu (KE) | Immune-cell activation models |
| Thymogen | Glu-Trp (EW) | Endothelial and immune signaling models |
Because these peptides are routinely tested together in the same papers, comparative in-vitro designs are common in this literature and generally more informative than single-compound studies.
Frequently Asked Questions
What is Pinealon?
Pinealon is the synthetic tripeptide Glu-Asp-Arg (EDR), CAS 175175-23-2, molecular weight approximately 418.41 g/mol. It is studied in laboratory research as a short peptide bioregulator, primarily in neuronal cell culture and rodent stress models.
What does the published research on Pinealon actually show?
In cell culture, published reports include restriction of reactive oxygen species accumulation in cerebellar granule cells, neutrophils, and PC12 cells; nuclear and nucleolar localization of fluorescently labeled peptide in HeLa cells; sequence-selective binding to DNA oligonucleotides; and, in a 2024 human induced-neuron aging model, increased dendritic arborization with reduced oxidative DNA damage. In rodents, an antihypoxic effect has been reported in hypobaric and prenatal hypoxia models.
How is Pinealon different from Epitalon?
They are different molecules studied in overlapping but distinct contexts. Pinealon is a tripeptide (EDR) associated mainly with neuronal oxidative-stress and hypoxia research. Epitalon is a tetrapeptide (AEDG) associated mainly with telomerase and pineal/circadian research. Several published studies test both side by side, and they should not be treated as interchangeable in experimental work.
Is there strong evidence behind Pinealon?
No. The evidence base is preclinical, largely single-lineage, and includes Russian-language sources that are difficult to assess independently. There are no completed randomized controlled trials. A January 2026 review noted the same gap. Researchers should treat published findings as hypothesis-generating.
Is Pinealon approved for any human use?
No. Pinealon is not an approved drug in the United States and is supplied strictly as a research chemical for in-vitro and laboratory research use only.
What is the purity level of Dynamite Research Peptides' Pinealon?
Our Pinealon is supplied at 99%+ purity as verified by analytical testing, with lot-specific results on the accompanying Certificate of Analysis.
Does Dynamite Research Peptides provide Certificates of Analysis (COAs)?
Yes. Every batch ships with a COA covering purity, identity, and other quality-control data, so researchers can confirm the material fits their experimental requirements before use.
Storage & Handling
Dynamite Research Peptides supplies Pinealon in lyophilized (freeze-dried) form. Store the powder at -20°C or below, protected from light and moisture. Reconstitute immediately before use with a suitable solvent following standard laboratory protocols, aliquot the reconstituted stock to avoid repeated freeze-thaw cycles, and consult the batch Certificate of Analysis for lot-specific handling notes. Short, highly charged peptides such as EDR are prone to adsorption onto glass and some plastics at low concentrations; low-binding tubes and consistent buffer conditions improve reproducibility across replicates. Use appropriate PPE and work in a well-ventilated laboratory area.
Conclusion
Pinealon (EDR) is best understood as a mechanistic probe rather than an established compound. Its most solid published support is biophysical — measurable, sequence-selective interaction with DNA, and documented nuclear localization of the labeled peptide — plus a 2024 human induced-neuron dataset showing selective effects on dendritic morphology and oxidative DNA damage. Its weakest point is the concentration of the biological literature in one research lineage and the complete absence of controlled clinical trials as of 2026. For laboratories studying ultrashort peptide–DNA interaction, neuronal responses to oxidative and hypoxic stress, or comparative bioregulator pharmacology, it is a relevant reference material. Our Pinealon is high-purity, third-party tested, and ships with a COA so results stay reliable and reproducible.
All products are for research use only (RUO) — not for human or animal consumption, and not for diagnostic or therapeutic use. The studies summarized above are described strictly as published scientific context; nothing in this article should be interpreted as medical guidance, a dosing recommendation, or a description of any effect of any product sold by Dynamite Research Peptides.
Last updated: August 11, 2026.